	US 12,246,032 B2
	Stabilized aqueous composition comprising chondroitin sulfate and hyaluronic acid
Eiji Nogami, Tokyo (JP); Akira Koushinbou, Tokyo (JP); Noriko Oshima, Tokyo (JP); Kota Fujiwara, Tokyo (JP); and Tomoya Sato, Tokyo (JP)
Assigned to SEIKAGAKU CORPORATION, Tokyo (JP)
Filed by Seikagaku Corporation, Tokyo (JP)
Filed on Jun. 7, 2022, as Appl. No. 17/834,796.
Application 17/834,796 is a continuation of application No. 16/935,922, filed on Jul. 22, 2020, abandoned.
Application 16/935,922 is a continuation of application No. 16/073,301, abandoned, previously published as PCT/JP2017/002858, filed on Jan. 27, 2017.
Claims priority of application No. 2016-015630 (JP), filed on Jan. 29, 2016.
Prior Publication US 2022/0296634 A1, Sep. 22, 2022
Int. Cl. A61K 31/737 (2006.01); A61K 9/00 (2006.01); A61K 31/728 (2006.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01)

CPC A61K 31/737 (2013.01) [A61K 9/0048 (2013.01); A61K 31/728 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01)]

13 Claims

1. A method for stabilizing a viscosity of an aqueous composition during storage, wherein the method comprises adding sorbitol in an aqueous composition which comprises 30 to 50 mg/mL of chondroitin sulfate or a salt thereof, 25 to 35 mg/mL of hyaluronic acid or a salt thereof, and a pharmaceutically acceptable carrier, thereby stabilizing the aqueous composition at room temperature, wherein after storage for 24 months in the dark at 25° C. and an RH (relative humidity) of 60% the aqueous composition has a viscosity of 20,000 to 120,000 mPa·s at 25° C. and at shear rate of 2 s⁻¹and wherein the aqueous composition is used for an ophthalmic surgical aid employed in an ophthalmic surgery for treating an ocular disease.